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Background: Although, substantial experimental evidence related to diagnosis and treatment of pediatric central
nervous system (CNS) neoplasms have been demonstrated, the understanding of the etiology and pathogenesis of
the disease remains scarce. Recent microRNA (miRNA)-based research reveals the involvement of miRNAs in various
aspects of CNS development and proposes that they might compose key molecules underlying oncogenesis. The
current study evaluated miRNA differential expression detected between pediatric embryonal brain tumors and
normal controls to characterize candidate biomarkers related to diagnosis, prognosis and therapy.
Methods: Overall, 19 embryonal brain tumors; 15 Medulloblastomas (MBs) and 4 Atypical Teratoid/Rabdoid Tumors
(AT/RTs) were studied. As controls, 13 samples were used; The First-Choice Human Brain Reference RNA and 12
samples from deceased children who underwent autopsy and were not present with any brain malignancy. RNA
extraction was carried out using the Trizol method, whilst miRNA extraction was performed with the mirVANA
miRNA isolation kit. The experimental approach included miRNA microarrays covering 1211 miRNAs. Quantitative
Real-Time Polymerase Chain Reaction was performed to validate the expression profiles of miR-34a and miR-601 in
all 32 samples initially screened with miRNA microarrays and in an additional independent cohort of 30 patients
(21MBs and 9 AT/RTs). Moreover, meta-analyses was performed in total 27 embryonal tumor samples; 19 MBs,
8 ATRTs and 121 control samples. Twelve germinomas were also used as an independent validation cohort. All
deregulated miRNAs were correlated to patients’ clinical characteristics and pathological measures.
Results: In several cases, there was a positive correlation between individual miRNA expression levels and laboratory or
clinical characteristics. Based on that, miR-601 could serve as a putative tumor suppressor gene, whilst miR-34a as an
oncogene. In general, miR-34a demonstrated oncogenic roles in all pediatric embryonal CNS neoplasms studied.
Conclusions: Deeper understanding of the aberrant miRNA expression in pediatric embryonal brain tumors might aid
in the development of tumor-specific miRNA signatures, which could potentially afford promising biomarkers related
to diagnosis, prognosis and patient targeted therapy.
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Central nervous system (CNS) pediatric tumors of em-
bryonal origin are a heterogeneous group of malignant
neoplasms that comprise by far the largest group of
malignant brain tumors in childhood. All embryonal
tumors are classified pathologically as grade IV malig-
nancies and they are largely comprised of medullo-
blastomas (MBs) and atypical teratoid/rhabdoid tumors
(AT/RTs), among others [1]. Medulloblastoma is con-
sidered the most common malignant pediatric brain
tumor, accounting for 20% of cases [2]. Risk stratifica-
tion based on clinical parameters is insufficient for ac-
curate prognostication [3]. Current treatment options
include surgery, chemotherapy and radiotherapy [4].
However, age limitations for the delivery of radio-
therapy have been set due to the vulnerability of the
developing brain to radiotherapy-induced neurocog-
nitive deficits [5]. Notwithstanding, aggressive multi-
modal therapy has improved the prognosis for children
with MB, nearly one third of patients will eventually
succumb to progressive tumors. Atypical teratoid/rhab-
doid tumour is also a highly malignant CNS tumour
that represents 1-2% of pediatric brain tumours and ac-
counts for at least 10% of CNS tumours in infants, due
to the predominance in children younger of 3 years old.
The survival of children younger than 3 years of age re-
mains poor, particularly for patients with supratentorial
tumors and those with metastatic disease [2]. It can be
supratentorial, especially in cerebral hem [6] ispheres,
or infratentorial, especially in the cerebellar hemispheres,
cerellopontine angle and brain stem mainly in children
younger than 2 years of age. Prognosis of AT/RT is dismal,
while there are no protocols aimed specifically for this
type [2].
The mainstay treatment for both local and distant dis-
ease control in older children, normally >3 years remains
craniospinal irradiation [7]. Nevertheless, outcomes re-
main highly associated with increased mortality due to
current therapy-resistant disease. It is therefore likely
that improved treatments will only be possible when the
tumor-specific molecular events are better understood.
Growing evidence suggests that a class of small cellu-
lar RNAs, termed microRNAs (miRNAs) play important
roles in controlling the development of the CNS, by
regulating cell proliferation, differentiation and apoptosis
[8,9]. Recent miRNA-based research reveals that a)
miRNA profiles of tumor cells are dissimilar from nor-
mal cells and b) miRNA expression profiles in tumors
from similar developmental origins have similar alter-
ations [10]. Understanding the interplay between normal
brain development and CNS tumors pathogenesis is es-
sential for the development and implementation of more
efficient and less toxic targeted therapies [4]. Given
these, and the fact that miRNAs are less susceptible tochemical modification and RNase degradation, provide
the rationale that miRNAs might afford substantial value
for neuro-oncology. Thus far, approaches to miRNA-
targeted therapies have been mentioned in lung cancer,
lymphoma and pancreatic cancer [11-14]. Regarding
brain tumors, to the best of our knowledge, there are no
reports available of miRNA use for therapeutic purposes,
except for in vitro systems [15,16]. In particular, the use
of miR-34a in several cancer models is encouraging,
since it has been found down-regulated in diverse types
of tumors [17-22] and its expression might suppress the
ontogenesis of those specific types of malignancies.
Undeniably, thus far, expression profile analysis has
revealed several miRNA signatures related to malignant
pediatric brain tumors [9,23-27]. However, as the num-
ber of novel miRNAs is still increasing, large-scale
screening is necessary to profile the global miRNA ex-
pression. To our knowledge, only a few studies applying
miRNA microarrays have been conducted [24,28,29] in
pediatric brain tumors. MiRNA microarrays afford the
most commonly used tool for the large-scale screening of
miRNA expression. Subsequently, bearing in mind that a)
miRNAs represent one of the largest classes of gene regu-
lators and b) the clinical significance of miRNA expression
profiles as well as their biological role in pediatric CNS
embryonal tumors remains to be elucidated, charac-
terization of miRNA patterns in pediatric malignant MBs
and AT/RTs might have substantial value for diagnostic
and prognostic purposes as well as for advanced thera-
peutic interventions.
In the current setting we performed for the first time
miRNA microarrays and meta-analyses based on miRNA
microarrays datasets from GEO to identify and validate
miRNA candidates relevant to pediatric CNS embryonal
prognosis. The obtained miRNA patterns were corre-
lated to several factors known to affect survival inclu-
ding tumor type, age at diagnosis and tumor recurrence.
We found that certain miRNA profiles were relevant to
each of the aforementioned variables and their possible
combinations delivering potential reliable diagnostic,
prognostic or therapy-related targets, while this is the
first report that underlines the adverse role of miR-34a
and its association with embryonal brain tumor patients’
inferior prognosis.Results
MicroRNA expression profiling between tumor groups
In the current study, we identified a total of 113 DE
miRNAs (p < 0.05 and FDR < 0.05) in the embryonal tumor
group (MBs, nmiRNA= 61 and AT/RTs, nmiRNA = 52) when
compared to the non-malignant group of patients (Figure 1).
Additionally, following meta-analysis 1242 DE miRNAs
were identified (p < 0.05 and FDR < 0.007).
AB
Figure 1 Histogram graphical representations of the differentially expressed miRNAs between embryonal tumors and the control
group. Comparisons between MBs and the control group (A). Comparisons between the AT/RTs and the control subjects (B). Y axis values represent
miRNA fold change. Overall, 113 miRNAs were found differentially expressed.
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served were down-regulated with a total of 54 miRNAs
(47.8%) exhibiting increased expression and 59 miRNAs
(52.2%) showing decreased expression. Among them, 107
miRNAs were characterized as tissue-specific, whilst 6miRNAs; miR-34a, miR-548j, miR-607, miR-891a, miR-
3191 and miR-3912 were found to be consistently diffe-
rentially expressed in both MBs and AT/RTs (Figure 2A).
Of note, the majority of them were also found differen-





Figure 2 Overlapping relationship of the differentially expressed miRNAs. Venn diagrams illustrate the overlapping relationship of the
number of up-regulated miRNAs among MBs and AT/RTs in initial and meta-analysis data. In particular, 6 DE miRNAs were common in MB and
ATRT samples from the initial experiments (A). Two were common in Down-regulated miRNAs between both MBs and ATRTs (B), as well as four
were common in up-regulated miRNAs between MBs and ATRTs (C). Further, 242 common down-regulated miRNAs were identified between
MBs, ATRT and GE samples in all experimental datasets (meta-analysis) (D). Additionally, six miRNAs appeared to be unique in Germinoma samples
(D). Finally, 150 miRNAs were identified to be common in up-regulated MB, ATRT and GE samples from the meta-analysis results (E). Additionally,
six miRNAs appeared to be unique in ATRT samples, within the same analysis, as well as 20 miRNAs were common between MB and GE samples
(E) (Legend: MB: Medulloblastoma, ATRT: Atypical Teratoid/Rhabdoid Tumor, GE: Germinoma).
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pressed in all embryonal tumor samples tested when com-
pared to the control group, following both our initial and
meta-analyses (including GEs) (Figure 2A, 2C, 2E). Fur-
ther on, miR-548j, miR-3191 and miR-3912 were found
overexpressed by our initial analysis only (Figure 2C),
whereas miR-607 and miR-891a were found down-
regulated in all embryonal tumor samples tested as com-
pared to the control group, following our initial analysis
only (Figure 2B). The overlapping relationship of the DE
miRNAs among both tumor types following initial and
meta-analyses is depicted in Figure 2. In addition, allcommonly down- or up-regulated miRNAs are presented
in Additional file 1: Table S2.
Unsupervised two-way hierarchical clustering (HCL)
with Euclidian distance confirmed that normal samples
and AT/RTs cluster independently, however it did not
discriminate accurately between MBs and the normal
control group (Figure 3). Following our initial analysis,
miRNA profiling did not discriminate between MBs and
the control group (Figure 3A). However, it appeared that
differences occurred regarding samples from cerebellum
and medulla oblongata (Additional file 2: Table S1).
MiRNA profiling accurately discriminated between AT/
AC
B
Figure 3 Hierarchical clustering (HCL). MiRNA profiling did not discriminate between MBs and the control group following initial analysis
(A). MiRNA profiling accurately discriminated between AT/RTs and the control group following initial analysis (B). Similarly, meta-analysis discriminated
between Embryonal tumors and GEs, yet by creating two groups of embryonal tumors (C).
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analysis discriminated between GEs and the rest em-
bryonal tumors (Figure 3C).
MicroRNA expression and patient age
Following our initial analysis, we evaluated differences
regarding patient age at diagnosis. Patients were divided
into three groups based on the therapeutic protocol they
received; Group A: < 3 years (n = 8), Group B: 3–8 years
(n = 4) and Group C: 9–18 years (n = 7). More specifi-
cally, Group A did not receive any radiation therapy,
whereas Group B and Group C received mild and more
intense radiation therapy, respectively. MiRNA expres-
sion associations were made among all aforementioned
individual patient groups. Following our initial analysis,
overall, 11 differentially expressed miRNAs were identi-
fied, including miR-1268, miR-2052, miR-26b, miR-3665,
miR-3681, miR-3912, miR-519c-3p, miR-601, miR-608,
miR-720 and miR-891a. Among them, 6 miRNAs;
miR-1268, miR-3681, miR-3912, miR-601, miR-608 and
miR-720 were overexpressed in Group A, 3 miRNAs;
miR-3665, miR-519c-3p and miR-891a were overexpressed
in Group B and 2 miRNAs; miR-2052 and miR-26b were
overexpressed in Group C. In addition, 3 miRNAs; miR-
519c-3p, miR-3665 and miR-891a were down-regulated in
Group A, 6 miRNAs; miR-1268, miR-2052, miR-26b, miR-
3912, miR-601 and miR-608 in Group B, whereas 2miRNAs; miR-720 and miR-3681 were down-regulated in
Group C (Additional file 3: Figure S2).
For the meta-analyses, individuals were age catego-
rized as following: Fetal; samples in gestation period
(n = 76), Infants; for individuals aged <1 year old (n = 19),
Children; for individuals >1 and <11 years old (n = 42),
Adolescents; for individuals >11 years and <18 years old
(n = 6) and Adults; for individuals >18 years old (n = 5).
Of note, using this type of analysis, similar results were
obtained. More specifically, all the aforementioned diffe-
rentially expressed miRNAs obtained, following the initial
analysis were once more found differentially expressed
after correlations with the new age categories. The only
miRNAs that were not validated were miR-3681 and
miR-608. All results are summarized in Additional
file 4: Table S3.
MicroRNA expression and gender
Overall, 8 miRNAs were found differentially expressed
when comparisons were performed between miRNA
expression levels and gender. Specifically, 3 miRNAs;
miR-26b, miR-3162 and miR-1268 were consistently
up-regulated in males, whilst 5 miRNAs including
miR-720, miR-186*, miR-3617, miR-320c and miR-
3614-5p were found overexpressed in females (Additional
file 5: Figure S3). Following meta-analysis, only miR-122*
was found differentially expressed between males and
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values (tumors/controls) and the natural values (no ratio,
no log2 transformation). The results are summarized in
Additional file 6: Table S3.
MicroRNA expression and disease progression
MicroRNA expression was compared between three
groups: control group, patient group in complete remis-
sion (CR) and relapsed (RE) patient group. In total, 18
miRNAs were found differentially expressed (Additional
file 7: Figure S4). Based on the current findings, 8 miR-
NAs; miR-3681, miR-601, miR-320e, miR-34a, miR-642a,
miR-136, miR-26b and miR-192 were found overex-
pressed in the patient group. Among them, 3 miRNAs
were found up-regulated in the RE patient group and 5
miRNAs were found overexpressed in the CR patient
group. In addition, 10 miRNAs; miR-720, miR-891a,
miR-522, miR-518c, miR-3665, miR-3620, miR-382, miR-
452, miR-122 and miR-147 were found down-regulated in
the patient group, indicating tumor suppressor properties.
Following meta-analysis, miR-122, miR-3162 and miR-
642a were found to be significantly different between RE
and CR samples in the log2, ratio transformed expression
values. Especially, miR-122 expression appeared to follow
a descending trend from MB to ATRT to GE. The
miR-122 tumor suppressor property was confirmed by







miR-3681 CR/R/C A/D/C Onco
miR-601 CR/R/C A/D/C Onco
miR-320e R/CR/C D/A/C Onco
miR-34a R/CR/C N/A Onco
miR-642a CR/R/C A/D/C Onco
miR-720 C/CR/R C/A/D Tum
miR-891a C/R/CR C/D/A Tum
miR-522 C/R/CR N/A Tum
miR-518c C/CR/R N/A Tum
miR-3665 C/CR/R N/A Tum
miR-3620 C/CR/R N/A Tum
miR-382 C/CR/R N/A Tum
miR-452 C/CR/R N/A Tum
miR-136 R/CR/C A/D/C Onco
miR-26b CR/R/C A/D/C Onco
miR-122 C/CR/R N/A Tum
miR-147 C/CR/R N/A Tum
miR-192 R/CR/C N/A Onco
High→ Low expression, CR; clinical remission, R; relapse, C; control, A; alive, D; decenatural values, miR-122 was found to be significantly dif-
ferent between control and RE samples as well as RE and
CR samples. Regarding miR-3162 expression, it followed
an ascending trend from MB to ATRT to GE. MiR-3162
and miR-642a were also found to be significantly different
in associations between RE and CR samples. Of note, the
oncogenic property of miR-642a as detected following the
initial analysis, was not confirmed by meta-analysis
(Table 1). The overexpression of miR-601 initially detected
as well as the down-regulation of miR-147 initially ob-
served were not validated. The results are summarized in
Additional file 6: Table S3.
MicroRNA expression and clinical outcome
MicroRNA expression was compared between three
groups: control group, patient group-survivors (alive) and
patient group-deceased. In total, 8 miRNAs were associa-
ted with patients’ clinical outcome; miR-3681, miR-601,
miR-320e, miR-642a, miR-720, miR-891a, miR-136 and
miR-26. Specifically, 2 miRNAs; miR-720a and miR-891a
were down-regulated and 6 miRNAs; miR320e, miR-3681,
miR-601, miR-642a, miR-136 and miR-26b were over-
expressed in the patient cohort when compared to the
control group. Based on the current findings, among the
overexpressed miRNAs, only miR320e was related to in-
ferior prognosis as it was significantly up-regulated in the






gene Tumor-suppressor gene Favorable
gene Tumor-suppressor gene Favorable
gene Oncogene Inferior
gene Tumor-suppressor gene Favorable
or-suppressor gene Tumor-suppressor gene Favorable
or-suppressor gene Tumor-suppressor gene Favorable
or-suppressor gene Oncogene Inferior
or-suppressor gene Oncogene Inferior
or-suppressor gene Tumor-suppressor gene Favorable
or-suppressor gene Tumor-suppressor gene Favorable
or-suppressor gene Tumor-suppressor gene Favorable
or-suppressor gene Tumor-suppressor gene Favorable
gene Oncogene Inferior
gene Oncogene Inferior
or-suppressor gene Tumor-suppressor gene Favorable
or-suppressor gene Oncogene Inferior
gene Oncogene Inferior
ased, P; positive, N/A; not applicable.
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miRNAs were associated with favorable prognosis, since
they were found to be consistently up-regulated in pa-
tients that remain alive when compared to the deceased
group of patients (Additional file 8: Figure S5). Following
meta-analyses, all 8 deregulated miRNAs that were iden-
tified initially were also found deregulated in previous
associations with disease progression. However, once
more, the overexpression of miR-601 initially detected
was not validated, suggesting tumor suppressor activities.
In addition, the oncogenic properties initially detected for
miR-642a and miR-320e were not confirmed with meta-
analyses suggesting tumor suppressor activities. However,
the oncogenic role of miR-3681, miR-26b and miR-136
were validated with meta-analyses (Table 1). The results
are summarized in Additional file 6: Table S3.
qRT-PCR validation
We verified by qRT-PCR the expression levels of miR-34a.
According to our results, miR-34a was found up-regulated
in all samples tested including the embryonal tumors
group and the MB group alone, following both initial
and meta-analyses. In addition, using the qRT-PCR raw
data from Ferretti et al. once again the up-regulation of
miR-34a in pediatric MBs was verified. Of note, the over-
expression of miR-34a was not validated in the AT/RT
group alone following initial analysis (Figure 4A). Re-
garding miR-601 initial analysis and meta-analyses did
not coincide as far as AT/RTs were concerned. The
qRT-PCR results revealed similar expression patterns
with meta-analyses regarding the embryonal tumors
group and the MB group alone (Figure 4B).
ROC analysis
ROC analysis of all miRNAs in each tumor type, using the
microarray expression data, evaluated the extent to which
they could separate each tumor entity from the control
group. The miRNAs with a p < 0.05 and an AUC > 0.8A B
Figure 4 Comparative diagram of Real-Time expression data with mic
MB and AT/RT samples by initial analysis, by Ferretti et al. microarray fold
Where: MB; Medulloblastoma, AT/RT; Atypical Terhatoid/Rhabdoid Tumorwere selected as successful distinguishing markers bet-
ween each tumor type and the control group (Figure 5).
More specifically, following the initial analysis the ROC
curves yielded the following AUCs: a) For MBs and
control group; miR-192 (AUC = 0.841, up-regulated)
(Figure 5C), b) For AT/RTs and control group; miR-34a
(AUC = 0.9, up-regulated) (Figure 5J). At the same time,
the meta-analysis confirmed most of the identified miR-
NAs. In particular, miR-34a (AUC = 0.911) (Figure 5A)
once again appeared to discriminate controls from em-
bryonal tumors.
Gene ontology and pathway analysis
Gene ontology analysis revealed that DE miRNAs
obtained from meta-analysis participated in three main
functions: RNA polyadenylation indicating a RNA pro-
cessing role, Autophagy implying a metabolic and pro-
bably survival role and pyrimidine synthesis indicating
proliferation (Figure 6). At the same time, pathway ana-
lysis did not show any significant pathway participation.
Yet, disease association analysis revealed that these DE
miRNAs participated in neoplasmatic diseases and neo-
plasm invasiveness (Additional file 4: Table S4).
Discussion
Previous research in various cancer disease processes sug-
gested that miRNAs play vital roles in disease patho-
genesis and have potential as biomarkers and therapeutic
agents. In particular, the use of miRNAs as embryonal
tumor markers constitutes an exciting field in biomedical
research, due to diverse aspects including ability to predict
disease before the onset of clinical symptoms, rich in-
formation content, great discriminatory power, accessi-
bility in different specimen types, possibility of being
evaluated from different sources and their potential for
accurate quantification following the application of high-
throughput technologies [30]. Yet, principally due to the
fact that the CNS is the least accessible of all tissues androarray expression. Comparison of Real-Time fold change of embryonal,
change by initial and meta-analyses for miR-34a (A) and miR-601 (B).
).
A B C D
E F G H
I J K L
M N O P
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Figure 5 ROC analysis of miRNA data. ROC curves of the differentially miRNAs in each tumor type using the microarray expression data.
Embryonal tumors could be separated by miR-34a (A) and miR-891a (B) following meta-analysis. MBs could be separated by miR-192 (C), miR-3617
(D) following initial analysis, whereas miR-3617 (E), miR-3912 (F), miR-4313 (G), miR-548j (H) and miR-548x (I) following meta-analysis. AT/RT samples
could be separated by miR-34a following initial analysis (J), miR-3617 following meta-analysis (K), miR-3912 following initial analysis (L), miR-3912
following meta-analysis (M), miR-4313 following initial-analysis (N), miR-4313 following meta-analysis (O), miR-548j following initial analysis
(P), miR-548j following meta-analysis (Q), miR-548x following initial analysis (R), miR-548x following meta-analysis (S), miR-607 following initial analysis
(T), miR- following initial analysis (U), miR-651 following initial analysis (V) and miR-891a following initial analysis (W). MiRNAs with a p < 0.05 and an
AUC > 0.8 were selected as successful distinguishing markers between tumor and normal tissues. Where miRLink; Initial Analysis, All Data; Meta-Analysis.
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Figure 6 GO annotation of the complete dataset. Three main functions were revealed: RNA polyadenylation, Autophagy and Pyrimidine
synthesis and processing.
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search, no embryonal tumor miRNA biomarkers have
been established in clinical practice [30,31].
In the current setting we performed miRNA micro-
arrays in pediatric patients with embryonal CNS neo-
plasms to investigate whether the differential expression
of miRNA genes is associated with factors that envisage
the clinical course of the disease. Ultimately, we aimed
to identify and provide additional data regarding poten-
tial miRNA expression signatures relative to prognosis
of pediatric MBs and AT/RTs, specifically. At present,
there have been comparatively limited reports focusing
on identifying miRNA biomarkers related to MB and
AT/RT diagnostics and therapeutics [23,26,28,32]. To
our knowledge, this is the first attempt aiding specifically
to evaluate an association between miRNA expression
patterns and disease progression or patient outcome in
pediatric MBs and AT/RTs and this is the first attempt
that used meta-analysis to validate findings.
By performing miRNA microarrays, we identified overall
113 differentially expressed miRNAs between embryonal
tumors and the control cohort. Among them, 107 were
tissue-specific and 6 miRNAs were common between the
two tumor types. More specifically, miR-34a, miR-548j,
miR-3191 and miR-3912 were found up-regulated in both
MBs and AT/RTs when compared to the control group.
Based on previous reports, miR-34a is considered a puta-
tive tumor suppressor gene in various types of cancers
[33-38] including brain tumors [39-42]. MiR-34a regulates
the expression of SIRT1 (silent information regulator 1),which functions as an oncogene by inactivating key tumor
suppressor proteins such as the transcription factor p53
[43-45]. Its targets include factors required for cell cycle
progression, anti-apoptotic proteins and proteins involved
in invasion [46].
In the current study, almost all analyses and asso-
ciations confirmed the up-regulation of miR-34a in the
embryonal tumors group and in the MB group alone.
Overexpression of miR-34a has been previously observed
in gastric cancer [47] as well as in pediatric brain tumors
including medulloblastomas [23], ependymomas [48]
pilocytic astrocytomas [28] and in low- and high-grade
astrocytomas [49]. More specifically, our meta-analyses
using the qRT-PCR raw data from Ferretti et al. [23], re-
vealed that miR-34a was up-regulated in the 34 patients
with MB that they screened. Additionally, according to
Costa et al. miR-34a was found up-regulated in all 34
pediatric ependymomas that they tested with qRT-PCR
against all normal samples. In Birks et al. [28] report, it
is also obvious that miR-34a was overexpressed in all
four pilocytic astrocytomas that they compared against a
total of eight normal pediatric brain specimens, using
miRNA microarrays. In addition, our meta-analysis
using their raw data revealed that miR-34a was also
overexpressed in all four MBs that they screened with
miRNA microarrays. Findings from Birks et al. [28] are
also in line with those reported by Ruiz Esparza-Garrido
et al. [49] who later demonstrated that miR-34a was up-
regulated in all twelve pediatric astrocytomas (3 pilocytic
astrocytomas, 4 diffuse astrocytomas and 5 glioblastoma
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four control brain tissues. Bearing in mind our miR-34a
findings, which a) have been validated with both ad-
ditional experimentation and meta-analyses using more
miRNA microarrays datasets and b) are in line with all
aforementioned previous reports, it seems likely that
miR-34a might not play global tumor suppressor roles.
For reliable conclusions to be drawn this should be vali-
dated in even larger patient cohorts.
Using a strict filtering approach in the ROC tests, we
determined a group of miRNAs that were also validated
in an independent patient cohort. Therefore, we suggest
that these miRNAs could be successfully used as distin-
guishing markers for each tumor type or between tumor
types and normal tissues. It is noteworthy, that among
them, once again, miR-34a was observed. In addition,
we showed that miR-548j, and miR-3912, which have
already manifested differential expression between em-
bryonal tumors and the control cohort, have a high
potential to distinguish AT/RTs alone from normal tis-
sues, affording significant potential diagnostic value for
AT/RTs. The role of miR-548j and miR-3912 is described
for first time in embryonal tumors, as no previous re-
lated reports were found. Moreover, we observed that
miR-192 and miR-3617 could accurately discriminate
MBs over the normal tissues indicating their potential as
putative biomarkers for MB diagnostics.
Overexpression of miR-192 contributes to tumor growth
and progression in pancreatic ductal adenocarcinoma [50],
and has been associated with early diagnosis of distant me-
tastasis of gastric cancer [51], and with clinical relevance
and prognostic significance in colon cancer [52]. Regarding
brain tumors, our results are in line with Ruiz-Esparza-
Garrido et al. [49], who manifested that miR-192 was up-
regulated in 5 high-grade astrocytomas, when compared to
7 low-grade ones. On the contrary, though, Liu et al. [53]
and Ferretti et al. [23] suggested that miR-192 was found
significantly down-regulated in eight pediatric gliomas and
in 34 pediatric MBs, respectively, whilst other reports in
pediatric brain tumors have not identified this gene as dif-
ferentially expressed [28,29,48,49,54]. Given these, the role
of miR-192 in childhood CNS malignancies remains to be
elucidated. No reports were found regarding the value of
miR-3617 in similar study groups.
Hierarchical clustering analysis using the miRNA sig-
natures revealed that AT/RTs formed distinct group
versus the controls, therefore assisting in the diagnosis
of this type of neoplasias. However, this was not dem-
onstrated in MBs. We would agree with Sredni et al.
[32] that miRNA expression profiling might not afford
the finest tool to classify brain tumors for diagnostic
purposes, especially in studies with small patient co-
horts. Additional studies have also failed to cluster ab-
solutely correct (100%) brain tumors based on miRNAexpression patterns [24,25,28,55]. To validate this re-
sult, we have utilized an independent group of GE tu-
mors. Germinomas are considered childhood tumors of
embryonic origin, arising from primordial germ cells
that have migrated aberrantly during embryonic devel-
opment and subsequently undergone malignant trans-
formation [56]. To investigate whether the inability of
HCL was due to samples’ relativeness or other technical
issues, we analyzed all data (MBs, AT/RTs, GEs) as a
common cohort. Subsequently, HCL successfully dis-
criminated between GEs and MBs or AT/RTs. This
finding might indicate that MBs and AT/RTs are very
close both in origin and in expression profiles. To our
knowledge, miRNA expression has been found indis-
putably distinct between tumor types or tumors versus
controls in one previous occasion [23].
The prognosis of early childhood medulloblastoma
treated with surgery, radiotherapy and chemotherapy has
been dismal (20%–45%) compared with older children,
probably due to a diverse biology underlying medulloblas-
toma in younger children [57]. In addition, whether the
molecular alterations described in embryonal tumors of
older children are consistent in infants remain to be
confirmed [7]. For this purpose we divided our patients
to different age groups based on treatment intervention
and we investigated potential distinct miRNA expres-
sion profiles. Overall, 11 miRNAs were found aberrantly
expressed. Among them, the most imperative miRNAs
with higher levels of expression obtained in youngest
children (Group A) and lower levels of expression in
older children (Group C) included miR-720 and miR-3681.
It is noteworthy, that 62.5% (5/8) of children remain alive
in Group A, although none of the children in this Group
received radiotherapy. In Group C, 57.1% (4/7) of patients
deceased from the embryonal tumor. In this Group, all
children have received intense radiotherapy in com-
bination with chemotherapy and surgery. It seems likely,
that overexpression of miR-720 and miR-3681 confers an
additional advantage to patients at higher-risk, whereas
down-regulation of these miRNAs reflects dismal progno-
sis to lower-risk groups of patients. No reports were found
about the value of miR-720 and miR-3681 in pediatric
CNS malignancies.
In the current study we also endeavored to identify
gender-specific miRNAs that could potentially contribute
susceptibility to embryonal brain malignancies. According
to Pinheiro et al. [58] notwithstanding the value of the X-
linked miRNAs remains to be elucidated, several miRNAs
participate in cancer onset and progression, while male pre-
ponderance has been observed in diverse types of cancer.
Nevertheless, among the differentially expressed miRNAs
identified in this setting, none of them was X located.
In an attempt to ascertain which miRNA signatures are
implicated in the progression and outcome of the disease,
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control tissue cohort and patient cohort including re-
lapsed patients and patients in complete remission as well
as control tissue cohort and patient cohort including
deceased patients and patients that remain alive, respec-
tively. Based on our findings, following both initial and
meta-analyses, we report the up-regulation of miR-3681,
miR-34a, miR-136, miR-26b and miR-192 in the patient
group, subsequently leading to the conclusion that they
might possess oncogenic activities. The expression profiles
initially obtained for miR-320e and miR-642a were not
validated with meta-analyses. In addition, it is noticeable
that the overexpression of miR-34a that we detected in
previous correlations was once more confirmed. This is in
line with Costa et al. [48] who also found miR-34a highly
overexpressed in ependymomas, however, according to
their results miR-34a portends a more favorable progno-
sis, instead. Yet again, miR-192 was found up-regulated in
the patient cohort, underlying the potential of this gene,
which according to our findings it emerges not only as a
putative diagnostic biomarker, but also as predictor for the
likelihood of an inferior clinical outcome.
Moreover, from current associations, although initially
miR-601 emerged as a putative oncogene, neither meta-
analysis nor qRT-PCR confirmed this finding. Therefore,
it seems likely that this gene has potential tumor sup-
pressor properties and our initial miRNA microarrays
analysis was inadequate to reveal this. Previous reports
were found describing both oncogenic and tumor sup-
pressor roles for miR-601. For instance, elevated expres-
sion levels for miR-601 have been previously reported in
pediatric ependymomas versus the control cohort and in
pediatric glioblastomas when compared to anaplastic
astrocytomas [25,48]. On the contrary, miR-601 might
serve as a novel biomarker for the clinical diagnosis of
colorectal cancer when down-regulated [55,59]. Based
on our results, we propose that miR-601 plays putative
tumor suppressor roles in MBs and its up-regulation is
subsequently associated with favorable prognosis. Also,
it is probable that it exerts tissue specific roles.
Remaining in the same context, both initial and meta-
analyses showed that miR-720, miR-891a, miR-3665,
miR-3620, miR-382, miR-452, and miR-122 were down-
regulated in the patient group and therefore indicating
that they might possess tumor-suppressive activities.
Previous reports also proposed a possible link between
these tumor-suppressor miRNA genes with diverse types
of malignancies, on several occasions. For instance, re-
duced levels of miR-720 and miR-382 have been hitherto
demonstrated in breast cancer [60,61] and MBs [23], re-
spectively. Down-regulation of miR-452 has been asso-
ciated with promoting stem-like traits and tumorigenesis
of gliomas and it has been suggested that it may repre-
sent a novel prognostic biomarker and therapeutic targetfor the disease [62]. In addition, miR-122, has been
well-documented to act as tumor-suppressor gene for
hepatocellular carcinoma [63,64] and breast cancer [65].
Regarding brain tumors, under expression of miRNA-122
has been demonstrated in glioma specimens and glioma
cell lines and has been inversely correlated with patients’
survival following surgery [66].
It is noteworthy, that the vast majority of the aforemen-
tioned miRNA oncogenes and tumor-suppressor genes
were also observed when comparisons were made be-
tween miRNA expression patterns and the disease out-
come, which verifies and validates their putative predictive
role, sometimes favorable and sometimes poor, in embry-
onal CNS malignancies. These results were also confirmed
by the regression analysis, which manifested both differen-
tial expressions in those miRNAs as well as linear behavior
between tumor types.
Functional annotation of the miRNA cohort indicated
that the DE miRNAs participate in RNA polyadenylation,
which includes RNA processing, autophagy and pyrimi-
dine synthesis. To the best of our knowledge, there are no
reports available regarding such associations. It could be
hypothesized that the identified miRNA cohort plays a
role in tumor progression, since autophagy has been re-
ported to be a survival mechanism in tumor cells [67]. At
the same time, RNA processing and nucleotide synthesis
are also signs of progressive disease, which probably could
be the case for the present miRNA cohort. Interestingly,
the identified miRNAs appeared to be of importance in
tumors as signified by the Disease Association annotation
analysis performed.
In summary, the current study was shown to provide
significant insights into the growing role of several
miRNA signatures in pediatric embryonal CNS neo-
plasms including MBs and AT/RTs. Following asso-
ciations with certain patients’ clinical characteristics and
cross-validation with meta-analyses, there was good
evidence that miR-601 emerged as a putative tumor
suppressor gene in MBs, whereas miR-34a manifested
potential oncogenic roles. This is the first study to report
the adverse properties of miR-34a as demonstrated in
pediatric embryonal brain neoplasms, indicating tissue-
specific roles rather than global tumor suppressor proper-
ties. Collectively, our findings modulated novel molecular
biomarkers which might have a promising potential in
pediatric embryonal CNS malignancies.
Methods
Patients and tumor samples
Initial analysis
Overall, 19 resected embryonal tumors were studied
from children diagnosed with MBs (n = 15) or AT/RTs
(n = 4) diagnosed according to the 2007 WHO criteria
[68]. Specifically, the patient cohort included 8 males
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4.56 ± 3.16 years). The median age of MB patients was
7.95 years with a male/female ratio of 1:1, the median
age for the AT/RT patients was 1.1 years with a male/
female ratio of 1:3, and the median age of the non-
malignant cohort was 9 years with a male/female ratio of
1:0. Among the patients’ cohort, 9 patients (47.4%) remain
in complete remission; 7 MB patients and 2 AT/RT pa-
tients, and 10 patients (52.6%) succumbed from the disease;
8 MB patients and 2 AT/RT patients. As controls, 13 sam-
ples were used; The First-Choice Human Brain Reference
RNA was used (Ambion, Austin, TX, USA) and 12 sam-
ples were obtained from four deceased children who
underwent autopsy and were not present with any brain
distortion, including the following anatomic locations:
cerebellum (n = 3), medulla oblongata (n = 3), parietal lobe
(n = 3) and temporal lobe (n = 3).
Haematoxylin and eosin (H&E) staining was performed
in all embryonal brain tumor specimens (Figure 7). All
samples were snap-frozen during resection and stored
at −80°C until use. Clinicopathologic information such as
age, tumor location, disease progression and survival for
each specimen were collected by retrospective medical
record review. The time of death was not available for the
majority of patients and as a result, the estimation of over-
all survival was not feasible. All samples are summarized
in Tables 2, 3 and presented thoroughly in Additional
file 2: Table S1. The present study was conducted with
the approval of “Aghia Sophia” Children’s Hospital Ethics
Committee (Protocol No. 35/19. 16/09/13).
Meta-analyses
In the present study, for validation and further cross-
analysis purposes, online available datasets; GSE193471
[69] and GSE451262 [70] and datasets from Birks et al.
(2011) [28] were included. From the GSE19347 dataset,
twelve germinoma (GE) samples were added as an inde-
pendent validating dataset, whereas from the GSE45126
dataset, 100 control samples were included. Lastly, from
Birks et al. (2011), four MBs, four ATRTs and eightA B
Figure 7 Representative haematoxylin and eosin (H&E) staining from
tumor (B).control samples were added. Subsequently, in total, our
meta-analysis included 39 CNS tumor samples; 19 MBs,
8 ATRTs, 12 GEs (not embryonal) and 121 control sam-
ples. All samples are summarized in Tables 2, 3 and pre-
sented thoroughly in Additional file 2: Table S1.
MicroRNA profiling
In brief, total RNA and miRNAs were extracted using the
Trizol standard protocol (Invitrogen, Carlsbad, CA) and the
mirVANA miRNA isolation kit (Ambion, Austin, TX). The
RNA quantity and quality were evaluated using a spectro-
photometer (NanoDrop® ND-1000 UV–vis, Nanogen Inc.).
Labelling and hybridization were performed using the
LabelIT miRNA labelling kit (Mirus Bio LLC, USA)
according to manufacturer’s instructions. Samples were
hybridized to Applied MicroArrays (miRlink Bioarray
300054-3PK) platform. This array contained 1211 human
miRNAs. Hybridization was performed at 37°C with
rotation at 145 rpm for 16 h. Images were scanned using
Agilent Microarray Scanner (G2565CA) controlled by
Agilent Scan Control 7.0 software.
Quantitative Real-Time Polymerase Chain Reaction
(qRT-PCR) validation
Expression measurements of selected targets (mature
miR-34a and miR-601) were studied in all tumor (n = 19)
and control samples used in the initial miRNA microarray
analysis and in an additional blinded independent set of
30 snap-frozen embryonal tumor samples (n = 21 MBs
and n = 9 AT/RTs) using qRT-PCR. In brief, cDNA syn-
thesis and subsequent RT-PCR were performed using a
TaqMan MiRNA Reverse Transcription kit (Applied
Biosystems, Inc., USA), and individual TaqMan MiRNA
assays (Applied Biosystems, Inc., USA), according to the
manufacturer’s recommendations. All samples were
tested in triplicate in a LC480 LightCycler system
(Roche GmbH, Switzerland). The RNU44 was used as
endogenous control. Wells lacking template were used
as negative controls. An additional online available
miRNA microarray MB dataset from Feretti et al. wasa non-malignant pediatric brain (cerebellum) (A) and an MB brain
Table 2 Clinical and demographic data of the patient cohort used in initial analysis
N All Males Females Medulloblastoma ATRT Germinoma Controls Mean age (years) STDEV age Mean age (weeks) STDEV age
Initial analysis ALL 32 6.15 4.74 331.14 227.61
MALES 22 8.41 4.98 439.46 238.84
FEMALES 10 4.12 3.42 233.65 164.39
UNKNOWN GENDER 0 NaN NaN NaN NaN
MEDULLOBLASTOMA 15 8 7 7.13 4.62 378.41 221.92
ATRT 4 1 3 2.46 3.06 153.90 146.95
GERMINOMA 0 0 0 NaN NaN NaN NaN
CONTROLS 13 13 0 NaN NaN NaN NaN
FETAL 0 0 0 0 0 0 0 NaN NaN NaN NaN
INFANT 3 1 2 1 2 0 0 0.34 0.30 52.53 14.18
CHILD 13 5 8 11 2 0 0 5.80 3.44 314.59 165.35
ADOLESCENT 3 3 0 3 0 0 0 13.45 1.85 681.48 88.71
ADULT 0 0 0 0 0 0 0 NaN NaN NaN NaN





MEDULLOBLASTOMA 46.88% 4.97% 4.35%
ATRT 12.50% 0.62% 1.86%
GERMINOMA 0.00% 0.00% 0.00%
CONTROLS 40.63% 8.07% 0.00%
FETAL 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
INFANT 9.38% 0.62% 1.24% 0.62% 1.24% 0.00% 0.00%
CHILD 40.63% 3.11% 4.97% 6.83% 1.24% 0.00% 0.00%
ADOLESCENT 9.38% 1.86% 0.00% 1.86% 0.00% 0.00% 0.00%














Table 3 Clinical and demographic data of the patient cohort used in the Meta-analysis
N All Males Females Unknown
gender








Meta-analysis ALL 161 4.15 11.91 226.32 574.91
MALES 82 3.85 13.76 210.26 663.33
FEMALES 46 1.09 2.43 76.16 122.39
UNKNOWN GENDER 32 9.20 14.00 476.79 672.56
MEDULLOBLASTOMA 19 8 7 4 6.89 4.13 366.95 198.43
ATRT 8 1 3 4 2.23 2.18 142.95 104.49
GERMINOMA 12 0 0 12 11.15 3.08 571.00 147.76
CONTROLS 121 73 36 12 3.04 13.43 169.45 647.52
FETAL 76 40 32 4 0 0 0 76 0.00 0.00 18.39 3.41
INFANT 19 15 4 0 1 2 0 16 0.56 0.54 62.67 25.71
CHILD 40 9 10 21 15 6 9 10 5.82 3.52 315.53 168.84
ADOLESCENT 6 3 0 3 3 0 3 0 14.07 1.57 711.54 75.34
ADULT 5 2 0 3 0 0 0 5 56.48 29.58 2746.94 1419.60





MEDULLOBLASTOMA 11.80% 4.97% 4.35% 2.48%
ATRT 4.97% 0.62% 1.86% 2.48%
GERMINOMA 7.45% 0.00% 0.00% 7.45%
CONTROLS 75.16% 45.34% 22.36% 7.45%
FETAL 47.20% 24.84% 19.88% 2.48% 0.00% 0.00% 0.00% 47.20%
INFANT 11.80% 9.32% 2.48% 0.00% 0.62% 1.24% 0.00% 9.94%
CHILD 24.84% 5.59% 6.21% 13.04% 9.32% 3.73% 5.59% 6.21%
ADOLESCENT 3.73% 1.86% 0.00% 1.86% 1.86% 0.00% 1.86% 0.00%
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pression changes were compared by relative quantifica-
tion in the form of fold changes obtained with the ΔΔCt
method.Statistical and data analyses
Microarray data extraction and pre-processing
The total gene signals were extracted using the Imagene
6.0 software (Biodiscovery Inc., USA) that contains sum-
marized signal intensities for each miRNA by combining
intensities of replicate probes and background subtrac-
tion. Raw data provided in the GEO database were used
for meta-analysis. All data were extracted, pre-processed
and sorted with Microsoft Excel®. Since each dataset had
a cohort of miRNAs, we had to follow a common meth-
odology for each dataset in order to obtain the max-
imum of common available miRNAs. This has been
succeeded using the following method: Each dataset had
a different number of replicates for each miRNA. There-
fore we created a new matrix, which included all avail-
able samples (set as columns) and all available miRNAs
(set as rows). This gave us a 19221 × 160 matrix, which
included all miRNAs and all their respective replicates
in all datasets. This matrix had numerous gaps, which
were filled with the “NaN” value.Microarray data analysis
The multiparameter analyses were performed with
MATLAB® simulation environment (The Mathworks, Inc,
Natick, MA). Since the final task was to calculate the
mean of each miRNA replicate, the matrix was uploaded
into the Matlab environment and “NaN” values were re-
placed as follows: for each miRNA the mean value was
calculated in the respective dataset and NaNs were re-
placed by that value. This did not change the total distri-
bution, while the mean of the miRNA remained the same.
In that way, we have managed to avoid NaNs, which fur-
ther on would interfere with our subsequent analysis.
Next, probe replicates were combined and the mean was
calculated, which was further used for analysis. Filtering
was performed based on the signal intensity. Background
correction was performed by subtracting the median local
background from the signal intensity as previously re-
ported [71]. Normalization was performed using the
quantile normalization algorithm. The two tailed student
t-test was used to test the mean differences between two
groups. Continuous variables were expressed as median ±
standard deviation unless differently indicated. Micro-
RNAs were considered to be significantly differentially
expressed (DE) if they obtained a p-value < 0.05 and an
FDR ≤ 0.05. Two-way average-linkage hierarchical cluster-
ing (HCL) with Euclidian distance was performed with
MATLAB® software. The normalization and microarraystatistical data analysis findings are presented in
Additional file 9: Figure S1.
Group-wise comparison of miRNA expression and clinical
data
MiRNA expression values were compared to clinical
parameters including gender, diagnosis, brain location,
tumor grade and developmental status (fetal, infancy,
childhood, adolescence, survival). Differences were consid-
ered significant if they obtained a p < 0.05.
ROC analysis
Receiver Operating Characteristic (ROC) curves were
established to evaluate the diagnostic value of differentially
expressed miRNAs for differentiation between CNS tu-
mors (MB, AT/RTs and GEs) and controls. ROC analysis
was performed with the MATLAB® simulation environ-
ment (The Mathworks, Inc, Natick, MA). ROC analysis
has been used in order to calculate Area Under the Curve
(AUC), along with Standard Error (SE) and 95% Confidence
Intervals (95% CI) [72]. ROC curves have been considered
significant if they obtained an AUC value >0.8 and a
p-value < 0.05.
MiRNA enrichment, gene ontology and pathway analysis
Differentially expressed miRNAs have been further
enriched and analyzed for known functions and known
pathway participation. This analysis was performed using










Additional file 1: Table S2. Common under- and up-regulated miRNAs
between tumors following initial and meta-analyses as from Venn diagrams.
Additional file 2: Table S1. Clinical Raw Data.
Additional file 3: Figure S2. MicroRNA expression levels and patient
age following initial analysis. Kruskal-Wallis analysis of miRNA expression
profiles between patient age groups; Group A: < 3 years, Group B: 3–8
years and Group C: 9–18 years. Overall, 11 differentially expressed miRNAs
were identified. Among them, 6 miRNAs were overexpressed in Group A
as compared to the other groups: miR-1268 (A), miR-3681 (B), miR-3912
(C), miR-601 (D), miR-608 (E) and miR-720 (F). Three miRNAs were
up-regulated in Group B as compared to the other groups: miR-3665 (G),
miR-519c-3p (H) and miR-891a (I). Finally, two miRNAs were up-regulated
as compared to the other groups: miR-2052 (J) and miR-26b (K).
(*denotes a p < 0.05 significance and **denotes a p < 0.01 significance).
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for DE miRNAs as predicted from enrichment analysis using WebGestalt
web tool.
Additional file 5: Figure S3. MicroRNA expression levels and patient
gender following initial analysis. Kruskal-Wallis analysis of miRNA expression
profiles between male and female patients within the miRLink dataset
(in-house experiments). In total, 3 miRNAs were up-regulated in males
miR-26b (A), miR-3162 (B) and miR-1268 (C), while 5 miRNAs were
overexpressed in females; miR-720 (D), miR-186* (E), miR-3617 (F), miR-320c
(G) and miR-3614-5p (H). (*denotes a p < 0.05 significance between pairs).
Additional file 6: Table S3. DE miRNAs log2 transformed and natural
mean expression values and statistical analysis between all clinical
associations.
Additional file 7: Figure S4. MicroRNA expression levels and disease
progression following initial analysis. Kruskal-Wallis analysis between
DE miRNAs and disease progression, following initial analysis; Relapse
(n = 9) or Complete Remission (n = 10) (CR). Overall, 18 miRNAs were
differentially expressed; 5 miRNAs were found up-regulated in the group
of patients that are in complete remission when compared to the relapsed
or the control groups; miR-3681 (A), miR-601 (B), miR-642a (C), miR-136
(D) and miR-26b (E). Additionally, three miRNAs were found up-regulated in
relapsed patients when compared to the group of patients that are in
Complete Remission (CR) or the control group; mIR-192 (F), miR-320e
(G) and miR-34a (H). Finally, ten miRNAs were found overexpressed in the
control group when compared to the patients group (relapsed or in Complete
Remission (CR)); miR-720 (I), miR-891a (J), miR-522 (K), miR-518c (L), miR-3665
(M), miR-891a (N), miR-382 (O), miR-452 (P), miR-122 (Q), miR-147 (R).
Additional file 8: Figure S5. MicroRNA expression levels and survival
following initial analysis. Kruskal-Wallis analysis between DE miRNAs and
patient outcome; alive (n = 9) or deceased (n = 10). In total, 8 miRNAs
were significantly different; five miRNAs weres found up-regulated in alive
patients when compared to the group of deceased and control samples.
In particular, miR-3681 (A), miR-642a (B), miR-26b (C), miR-136 (D) and
miR-320e (E) were increased in alive samples as well as manifested linear
regression with respect to expression moving from alive samples to controls.
Two miRNAs were found down-regulated in the group of patients that remain
alive when compared to the diseased or the control groups. In particular,
miR-720 (F) and miR-891a (G) manifested similar linear regression increasing
from alive samples to controls. Finally, one miRNA, miR-320c (H), manifested
higher expression levels in deceased samples as compared to alive and
control samples (* denotes a p < 0.05 significance).
Additional file 9: Figure S1. Analysis results of microarray data.
Quantile normalization (A), T-test histograms (B), Volcano plot of T-test
results (C), False Discovery Rate (FDR) of T-test results (D).
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